Skip to content
Otsuka Pharmaceutical
-
FDA approves Otsuka’s Simtriyo as first-in-class NDSRI for ADHD treatment
The approval makes Simtriyo the first norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for ADHD and gives Otsuka what Jefferies analysts described as its “next major CNS launch.”
-
Otsuka Pharmaceutical acquires Transcend Therapeutics in USD1.2B PTSD drug deal
Central to this deal is TSND-201, also known as methylone, Transcend’s lead experimental drug for post-traumatic stress disorder (PTSD) and other psychiatric conditions.